The role of the CLL-1 protein in disease monitoring in patients diagnosed with acute myeloid leukaemia and myelodysplastic syndrome

Pol J Pathol. 2024;75(3):182-191. doi: 10.5114/pjp.2024.143228.

Abstract

The normal subpopulation of CD34+CD38 - haematopoietic stem cells does not express CLL-1; therefore, the assessment of the expression of this protein can be used for the diagnosis of minimal residual disease. The aim of this study was to evaluate, using multi-colour flow cytometry, the level of CLL-1 protein expression on CD34+CD38- myeloid niche cells in acute myeloid leukaemia (AML) and myelodysplastic syndromepatients at the time of diagnosis and during disease monitoring on the example of 3 practical cases. The following conclusion was drawn: CD34+CD38-CLL-1+ cells in AML patients may serve as a biomarker to predict disease aggressiveness.

Keywords: CLL-1; MDS; multi-colour flow cytometry.; AML.

Publication types

  • Case Reports

MeSH terms

  • ADP-ribosyl Cyclase 1 / analysis
  • ADP-ribosyl Cyclase 1 / metabolism
  • Aged
  • Biomarkers, Tumor* / analysis
  • Biomarkers, Tumor* / metabolism
  • Female
  • Flow Cytometry*
  • Humans
  • Lectins, C-Type
  • Leukemia, Myeloid, Acute* / diagnosis
  • Leukemia, Myeloid, Acute* / pathology
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes* / diagnosis
  • Myelodysplastic Syndromes* / pathology
  • Neoplasm, Residual
  • Receptors, Mitogen

Substances

  • Biomarkers, Tumor
  • CLEC12A protein, human
  • ADP-ribosyl Cyclase 1
  • Receptors, Mitogen
  • Lectins, C-Type